首页 > 最新文献

Archives of pathology & laboratory medicine最新文献

英文 中文
Don't Fear the Artificial Intelligence: A Systematic Review of Machine Learning for Prostate Cancer Detection in Pathology. 不要惧怕人工智能:病理学中前列腺癌检测机器学习的系统回顾。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2022-0460-RA
Aaryn Frewing, Alexander B Gibson, Richard Robertson, Paul M Urie, Dennis Della Corte

Context: Automated prostate cancer detection using machine learning technology has led to speculation that pathologists will soon be replaced by algorithms. This review covers the development of machine learning algorithms and their reported effectiveness specific to prostate cancer detection and Gleason grading.

Objective: To examine current algorithms regarding their accuracy and classification abilities. We provide a general explanation of the technology and how it is being used in clinical practice. The challenges to the application of machine learning algorithms in clinical practice are also discussed.

Data sources: The literature for this review was identified and collected using a systematic search. Criteria were established prior to the sorting process to effectively direct the selection of studies. A 4-point system was implemented to rank the papers according to their relevancy. For papers accepted as relevant to our metrics, all cited and citing studies were also reviewed. Studies were then categorized based on whether they implemented binary or multi-class classification methods. Data were extracted from papers that contained accuracy, area under the curve (AUC), or κ values in the context of prostate cancer detection. The results were visually summarized to present accuracy trends between classification abilities.

Conclusions: It is more difficult to achieve high accuracy metrics for multiclassification tasks than for binary tasks. The clinical implementation of an algorithm that can assign a Gleason grade to clinical whole slide images (WSIs) remains elusive. Machine learning technology is currently not able to replace pathologists but can serve as an important safeguard against misdiagnosis.

背景:使用机器学习技术进行前列腺癌自动检测已引发了病理学家很快将被算法取代的猜测。本综述涉及机器学习算法的发展及其在前列腺癌检测和格里森分级方面的有效性:目的:研究当前算法的准确性和分类能力。我们将对该技术及其在临床实践中的应用进行总体解释。我们还讨论了在临床实践中应用机器学习算法所面临的挑战:本综述的文献是通过系统搜索确定和收集的。在分类过程之前,我们制定了标准,以有效指导研究的选择。根据论文的相关性,我们采用了一个 4 点系统对论文进行排序。对于被认为与我们的衡量标准相关的论文,我们还审查了所有被引用和引用的研究。然后,根据研究是否采用了二元或多类分类方法对其进行分类。从包含前列腺癌检测准确率、曲线下面积(AUC)或κ值的论文中提取数据。对结果进行了直观总结,以呈现不同分类能力之间的准确率趋势:结论:与二元任务相比,多重分类任务更难获得高准确度指标。能够为临床全切片图像(WSI)分配格里森分级的算法的临床实施仍然遥遥无期。机器学习技术目前还不能取代病理学家,但可以作为防止误诊的重要保障。
{"title":"Don't Fear the Artificial Intelligence: A Systematic Review of Machine Learning for Prostate Cancer Detection in Pathology.","authors":"Aaryn Frewing, Alexander B Gibson, Richard Robertson, Paul M Urie, Dennis Della Corte","doi":"10.5858/arpa.2022-0460-RA","DOIUrl":"10.5858/arpa.2022-0460-RA","url":null,"abstract":"<p><strong>Context: </strong>Automated prostate cancer detection using machine learning technology has led to speculation that pathologists will soon be replaced by algorithms. This review covers the development of machine learning algorithms and their reported effectiveness specific to prostate cancer detection and Gleason grading.</p><p><strong>Objective: </strong>To examine current algorithms regarding their accuracy and classification abilities. We provide a general explanation of the technology and how it is being used in clinical practice. The challenges to the application of machine learning algorithms in clinical practice are also discussed.</p><p><strong>Data sources: </strong>The literature for this review was identified and collected using a systematic search. Criteria were established prior to the sorting process to effectively direct the selection of studies. A 4-point system was implemented to rank the papers according to their relevancy. For papers accepted as relevant to our metrics, all cited and citing studies were also reviewed. Studies were then categorized based on whether they implemented binary or multi-class classification methods. Data were extracted from papers that contained accuracy, area under the curve (AUC), or κ values in the context of prostate cancer detection. The results were visually summarized to present accuracy trends between classification abilities.</p><p><strong>Conclusions: </strong>It is more difficult to achieve high accuracy metrics for multiclassification tasks than for binary tasks. The clinical implementation of an algorithm that can assign a Gleason grade to clinical whole slide images (WSIs) remains elusive. Machine learning technology is currently not able to replace pathologists but can serve as an important safeguard against misdiagnosis.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"603-612"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10082587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Performance of the Line Immunoassay, Digital Liquid Chip Method, and Chemiluminescent Immunoassay for Detecting Specific Antinuclear Antibodies. 检测特异性抗核抗体的线性免疫测定法、数字液体芯片法和化学发光免疫测定法的临床表现。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2022-0331-OA
Zhenzhen Su, Li Wang, Xuedan Gao, Zhuochun Huang, Jing Hu, Bin Yang

Context: Antinuclear antibodies (ANAs) against certain antigens are useful for identifying autoimmune disorders. Although new solid phase-based immunoassays have been developed for evaluating ANAs, the conventional line immunoassay (LIA) is commonly used in clinical practice.

Objective: To compare the clinical performance of 2 newly developed methods for detecting specific ANAs with LIA.

Design: Six hundred ninety-six serum samples were collected from 559 patients with autoimmune disease (AID) and 137 controls. The samples were screened by using the LIA, digital liquid chip method (DLCM), and chemiluminescent immunoassay (CLIA) for specific ANAs. The agreement across assays and the clinical performance of each assay in diagnosing ANA-associated rheumatic diseases (AARDs) were evaluated.

Results: Almost perfect agreement was observed among all assays for anti-centromere protein B (κ = 0.85-0.97), anti-ribosome P (κ = 0.85-0.88), anti-SSA 52 (κ = 0.86-0.89), and anti-SSA 60 (κ = 0.89-0.91); moderate to substantial agreement was detected for the autoantibodies against Sm, Jo-1, ribonucleoprotein, Scl-70, and SSB (κ = 0.55-0.80). LIA exhibited better sensitivity for diagnosing AARDs, while DLCM and CLIA demonstrated higher specificity. In the subset of AIDs, especially systemic lupus erythematosus, antibody positive percentages varied greatly between assays.

Conclusions: The 3 assays showed comparable qualitative agreement; however, the standardization of testing for ANAs remains challenging owing to intermanufacturer variations. Moreover, DLCM and CLIA exhibited better specificity in distinguishing non-AID individuals, whereas LIA was more sensitive in diagnosing AARDs.

背景:针对某些抗原的抗核抗体(ANAs)有助于鉴别自身免疫性疾病。尽管目前已开发出新的固相免疫测定法来评估 ANA,但传统的线性免疫测定法(LIA)在临床实践中仍被普遍使用:比较两种新开发的检测特异性 ANA 的方法与 LIA 的临床性能:从 559 名自身免疫性疾病 (AID) 患者和 137 名对照组患者中采集了 696 份血清样本。采用 LIA、数字液体芯片法 (DLCM) 和化学发光免疫分析法 (CLIA) 对样本进行了特异性 ANA 筛选。评估了各种检测方法之间的一致性以及每种检测方法在诊断 ANA 相关风湿性疾病(AARDs)方面的临床表现:结果:在抗中心粒蛋白B(κ = 0.85-0.97)、抗核糖体P(κ = 0.85-0.88)、抗SSA 52(κ = 0.86-0.89)和抗SSA 60(κ = 0.89-0.91)方面,所有检测方法几乎完全一致;在抗Sm、Jo-1、核糖核蛋白、Scl-70和SSB的自身抗体(κ = 0.55-0.80)方面,检测结果基本一致。LIA 在诊断 AARDs 方面表现出更高的灵敏度,而 DLCM 和 CLIA 则表现出更高的特异性。在艾滋病子集中,尤其是系统性红斑狼疮,不同检测方法的抗体阳性率差异很大:结论:三种检测方法显示出相似的定性一致性;然而,由于生产商之间的差异,ANA 检测的标准化仍具有挑战性。此外,DLCM 和 CLIA 在区分非艾滋病患者方面表现出更好的特异性,而 LIA 在诊断 AARDs 方面更为敏感。
{"title":"Clinical Performance of the Line Immunoassay, Digital Liquid Chip Method, and Chemiluminescent Immunoassay for Detecting Specific Antinuclear Antibodies.","authors":"Zhenzhen Su, Li Wang, Xuedan Gao, Zhuochun Huang, Jing Hu, Bin Yang","doi":"10.5858/arpa.2022-0331-OA","DOIUrl":"10.5858/arpa.2022-0331-OA","url":null,"abstract":"<p><strong>Context: </strong>Antinuclear antibodies (ANAs) against certain antigens are useful for identifying autoimmune disorders. Although new solid phase-based immunoassays have been developed for evaluating ANAs, the conventional line immunoassay (LIA) is commonly used in clinical practice.</p><p><strong>Objective: </strong>To compare the clinical performance of 2 newly developed methods for detecting specific ANAs with LIA.</p><p><strong>Design: </strong>Six hundred ninety-six serum samples were collected from 559 patients with autoimmune disease (AID) and 137 controls. The samples were screened by using the LIA, digital liquid chip method (DLCM), and chemiluminescent immunoassay (CLIA) for specific ANAs. The agreement across assays and the clinical performance of each assay in diagnosing ANA-associated rheumatic diseases (AARDs) were evaluated.</p><p><strong>Results: </strong>Almost perfect agreement was observed among all assays for anti-centromere protein B (κ = 0.85-0.97), anti-ribosome P (κ = 0.85-0.88), anti-SSA 52 (κ = 0.86-0.89), and anti-SSA 60 (κ = 0.89-0.91); moderate to substantial agreement was detected for the autoantibodies against Sm, Jo-1, ribonucleoprotein, Scl-70, and SSB (κ = 0.55-0.80). LIA exhibited better sensitivity for diagnosing AARDs, while DLCM and CLIA demonstrated higher specificity. In the subset of AIDs, especially systemic lupus erythematosus, antibody positive percentages varied greatly between assays.</p><p><strong>Conclusions: </strong>The 3 assays showed comparable qualitative agreement; however, the standardization of testing for ANAs remains challenging owing to intermanufacturer variations. Moreover, DLCM and CLIA exhibited better specificity in distinguishing non-AID individuals, whereas LIA was more sensitive in diagnosing AARDs.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"566-572"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10082588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Cognitive Framework Behind Modern Neuropathology. 现代神经病理学背后的认知框架。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0209-RA
José Javier Otero

Context: In 2021 the World Health Organization distributed a new classification of central nervous system tumors that incorporated modern testing modalities in the diagnosis. Although universally accepted as a scientifically superior system, this schema has created controversy because its deployment globally is challenging in the best of circumstances and impossible in resource-poor health care ecosystems. Compounding this problem is the significant challenge that neuropathologists with expertise in central nervous system tumors are rare.

Objective: To demonstrate diagnostic use of simple unsupervised machine learning techniques using publicly available data sets. I also discuss some potential solutions to the deployment of neuropathology classification in health care ecosystems burdened by this classification schema.

Data sources: The Cancer Genome Atlas RNA sequencing data from low-grade and high-grade gliomas.

Conclusions: Methylation-based classification will be unable to solve all diagnostic problems in neuropathology. Information theory quantifications generate focused workflows in pathology, resulting in prevention of ordering unnecessary tests and identifying biomarkers that facilitate diagnosis.

背景:2021 年,世界卫生组织发布了新的中枢神经系统肿瘤分类法,将现代检测模式纳入诊断。尽管该分类法被普遍认为是科学上更优越的系统,但却引发了争议,因为在最好的情况下,在全球范围内采用该分类法具有挑战性,而在资源匮乏的医疗保健生态系统中则是不可能的。使这一问题更加复杂的是,具有中枢神经系统肿瘤专业知识的神经病理学家非常罕见:目的:利用公开数据集展示简单的无监督机器学习技术在诊断中的应用。我还将讨论一些潜在的解决方案,以便在受这种分类模式影响的医疗保健生态系统中部署神经病理学分类:癌症基因组图谱》(Cancer Genome Atlas)中低级别和高级别胶质瘤的 RNA 测序数据:基于甲基化的分类无法解决神经病理学中的所有诊断问题。信息论量化可生成病理学中重点突出的工作流程,从而避免开具不必要的检验单,并确定有助于诊断的生物标记物。
{"title":"The Cognitive Framework Behind Modern Neuropathology.","authors":"José Javier Otero","doi":"10.5858/arpa.2023-0209-RA","DOIUrl":"10.5858/arpa.2023-0209-RA","url":null,"abstract":"<p><strong>Context: </strong>In 2021 the World Health Organization distributed a new classification of central nervous system tumors that incorporated modern testing modalities in the diagnosis. Although universally accepted as a scientifically superior system, this schema has created controversy because its deployment globally is challenging in the best of circumstances and impossible in resource-poor health care ecosystems. Compounding this problem is the significant challenge that neuropathologists with expertise in central nervous system tumors are rare.</p><p><strong>Objective: </strong>To demonstrate diagnostic use of simple unsupervised machine learning techniques using publicly available data sets. I also discuss some potential solutions to the deployment of neuropathology classification in health care ecosystems burdened by this classification schema.</p><p><strong>Data sources: </strong>The Cancer Genome Atlas RNA sequencing data from low-grade and high-grade gliomas.</p><p><strong>Conclusions: </strong>Methylation-based classification will be unable to solve all diagnostic problems in neuropathology. Information theory quantifications generate focused workflows in pathology, resulting in prevention of ordering unnecessary tests and identifying biomarkers that facilitate diagnosis.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"e103-e110"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10202303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loose Tumor Cells in Pulmonary Arteries of Lung Adenocarcinoma Resection Specimens: No Correlation With Survival, Despite High Prevalence. 肺腺癌切除标本肺动脉中的松散肿瘤细胞:尽管发病率很高,但与存活率无关
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0009-OA
Hans Blaauwgeers, Federica Filipello, Birgit Lissenberg-Witte, Claudio Doglioni, Teodora Radonic, Idris Bahce, Yuko Minami, Andreas Schonau, Julien P L Vincenten, Adrianus A J Smit, Chris Dickhoff, Erik Thunnissen

Context: Loose tumor cells and tumor cell clusters can be recognized in the lumen of intratumoral pulmonary arteries of resected non-small cell lung cancer specimens. It is unclear whether these should be considered tumor-emboli, and as such could predict a worsened prognosis.

Objective: To investigate the nature and prognostic impact of pulmonary artery intraluminal tumor cells.

Design: This multicenter study involved an exploratory pilot study and a validation study from 3 institutions. For the exploratory pilot study, a retrospective pulmonary resection cohort of primary adenocarcinomas, diagnosed between November 2007 and November 2010, were scored for the presence of tumor cells, as well as potentially other cells in the intravascular spaces, using hematoxylin-eosin and cytokeratin 7 (CK7) stains. In the validation part, 2 retrospective cohorts of resected pulmonary adenocarcinomas, between January 2011 and December 2016, were included. Recurrence-free survival (RFS) and overall survival (OS) data were collected.

Results: In the pilot study, CK7+ intravascular cells, mainly tumor cells, were present in 23 of 33 patients (69.7%). The 5-year OS for patients with intravascular tumor cells was 61%, compared with 40% for patients without intravascular tumor cells (P = .19). In the validation study, CK7+ intravascular tumor cells were present in 41 of 70 patients (58.6%). The 5-year RFS for patients with intravascular tumor cells was 80.0%, compared with 80.6% in patients without intravascular tumor cells (P = .52). The 5-year OS rates were, respectively, 82.8% and 71.6% (P = .16).

Conclusions: Loose tumor cells in pulmonary arterial lumina were found in most non-small cell lung cancer resection specimens and were not associated with a worse RFS or OS. Therefore, most probably they represent an artifact.

背景:在切除的非小细胞肺癌标本的瘤内肺动脉管腔中可发现松散的肿瘤细胞和肿瘤细胞簇。目前尚不清楚这些是否应被视为肿瘤栓子,并因此可预测预后恶化:研究肺动脉腔内肿瘤细胞的性质及其对预后的影响:这项多中心研究包括一项探索性试验研究和一项验证研究,分别来自 3 家机构。在探索性试点研究中,采用苏木精-伊红和细胞角蛋白7(CK7)染色法,对2007年11月至2010年11月期间确诊的原发性腺癌的回顾性肺切除队列中是否存在肿瘤细胞以及血管内间隙中可能存在的其他细胞进行评分。在验证部分,纳入了 2011 年 1 月至 2016 年 12 月间切除的肺腺癌的两个回顾性队列。研究收集了无复发生存期(RFS)和总生存期(OS)数据:在试点研究中,33例患者中有23例(69.7%)存在CK7+血管内细胞,主要是肿瘤细胞。有血管内肿瘤细胞的患者的5年生存率为61%,而没有血管内肿瘤细胞的患者的5年生存率为40%(P = .19)。在验证研究中,70 例患者中有 41 例(58.6%)存在 CK7+ 血管内肿瘤细胞。有血管内肿瘤细胞的患者的5年RFS为80.0%,而无血管内肿瘤细胞的患者为80.6%(P = .52)。5年OS率分别为82.8%和71.6%(P = .16):结论:大多数非小细胞肺癌切除标本中都发现了肺动脉管腔内的松散肿瘤细胞,但它们与较差的RFS或OS无关。因此,它们很可能是一种假象。
{"title":"Loose Tumor Cells in Pulmonary Arteries of Lung Adenocarcinoma Resection Specimens: No Correlation With Survival, Despite High Prevalence.","authors":"Hans Blaauwgeers, Federica Filipello, Birgit Lissenberg-Witte, Claudio Doglioni, Teodora Radonic, Idris Bahce, Yuko Minami, Andreas Schonau, Julien P L Vincenten, Adrianus A J Smit, Chris Dickhoff, Erik Thunnissen","doi":"10.5858/arpa.2023-0009-OA","DOIUrl":"10.5858/arpa.2023-0009-OA","url":null,"abstract":"<p><strong>Context: </strong>Loose tumor cells and tumor cell clusters can be recognized in the lumen of intratumoral pulmonary arteries of resected non-small cell lung cancer specimens. It is unclear whether these should be considered tumor-emboli, and as such could predict a worsened prognosis.</p><p><strong>Objective: </strong>To investigate the nature and prognostic impact of pulmonary artery intraluminal tumor cells.</p><p><strong>Design: </strong>This multicenter study involved an exploratory pilot study and a validation study from 3 institutions. For the exploratory pilot study, a retrospective pulmonary resection cohort of primary adenocarcinomas, diagnosed between November 2007 and November 2010, were scored for the presence of tumor cells, as well as potentially other cells in the intravascular spaces, using hematoxylin-eosin and cytokeratin 7 (CK7) stains. In the validation part, 2 retrospective cohorts of resected pulmonary adenocarcinomas, between January 2011 and December 2016, were included. Recurrence-free survival (RFS) and overall survival (OS) data were collected.</p><p><strong>Results: </strong>In the pilot study, CK7+ intravascular cells, mainly tumor cells, were present in 23 of 33 patients (69.7%). The 5-year OS for patients with intravascular tumor cells was 61%, compared with 40% for patients without intravascular tumor cells (P = .19). In the validation study, CK7+ intravascular tumor cells were present in 41 of 70 patients (58.6%). The 5-year RFS for patients with intravascular tumor cells was 80.0%, compared with 80.6% in patients without intravascular tumor cells (P = .52). The 5-year OS rates were, respectively, 82.8% and 71.6% (P = .16).</p><p><strong>Conclusions: </strong>Loose tumor cells in pulmonary arterial lumina were found in most non-small cell lung cancer resection specimens and were not associated with a worse RFS or OS. Therefore, most probably they represent an artifact.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"588-594"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Molecular Discoveries Have Changed Liver Tumor Pathology: A Brief Review. 分子发现如何改变肝脏肿瘤病理学?简要回顾。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0099-RA
Negar Taheri, Rondell P Graham

Context: Recent molecular discoveries have led to improved understanding of tumor biology and the development of new diagnostic assays.

Objective: To review primarily 3 examples of liver tumors and to briefly illustrate how recent molecular discoveries have altered clinical liver pathology practice.

Data sources: First, we will discuss fibrolamellar carcinoma, which will be the main focus of discussion, as an example for new diagnostic tests that have been developed as a result of molecular discoveries. Additional information on the role of molecular diagnostics in hepatocellular adenoma and hepatocellular carcinoma will be provided. Second, we will use the example of epithelioid hemangioendothelioma as an example of how new diagnostic tools, based on molecular discoveries, may support improved prognostication. Finally, we will use the example of intrahepatic cholangiocarcinoma as an example of a liver tumor where new molecular discoveries have identified tractable therapeutic targets and led to new effective therapies. This portion of the manuscript will also include a description of the anatomic and molecular differences between intrahepatic, hilar, and extrahepatic cholangiocarcinoma.

Conclusions: Fueled by molecular discoveries, new and better diagnostic tests and therapeutic targets have improved clinical care in patients affected by liver tumors.

背景:最近的分子发现提高了人们对肿瘤生物学的认识,并开发了新的诊断方法:主要回顾 3 个肝脏肿瘤实例,简要说明最新的分子发现如何改变了临床肝脏病理学实践:首先,我们将讨论纤维母细胞瘤,这将是讨论的重点,并以此为例说明由于分子发现而开发的新诊断检测方法。我们还将提供有关分子诊断在肝细胞腺瘤和肝细胞癌中的作用的补充信息。其次,我们将以上皮样血管内皮细胞瘤为例,说明基于分子发现的新诊断工具如何有助于改善预后。最后,我们将以肝内胆管癌为例,说明在肝脏肿瘤中,新的分子发现发现了可治疗的靶点,并带来了新的有效疗法。手稿的这一部分还将包括对肝内胆管癌、肝门胆管癌和肝外胆管癌之间的解剖和分子差异的描述:在分子发现的推动下,新的、更好的诊断测试和治疗目标改善了肝肿瘤患者的临床治疗。
{"title":"How Molecular Discoveries Have Changed Liver Tumor Pathology: A Brief Review.","authors":"Negar Taheri, Rondell P Graham","doi":"10.5858/arpa.2023-0099-RA","DOIUrl":"10.5858/arpa.2023-0099-RA","url":null,"abstract":"<p><strong>Context: </strong>Recent molecular discoveries have led to improved understanding of tumor biology and the development of new diagnostic assays.</p><p><strong>Objective: </strong>To review primarily 3 examples of liver tumors and to briefly illustrate how recent molecular discoveries have altered clinical liver pathology practice.</p><p><strong>Data sources: </strong>First, we will discuss fibrolamellar carcinoma, which will be the main focus of discussion, as an example for new diagnostic tests that have been developed as a result of molecular discoveries. Additional information on the role of molecular diagnostics in hepatocellular adenoma and hepatocellular carcinoma will be provided. Second, we will use the example of epithelioid hemangioendothelioma as an example of how new diagnostic tools, based on molecular discoveries, may support improved prognostication. Finally, we will use the example of intrahepatic cholangiocarcinoma as an example of a liver tumor where new molecular discoveries have identified tractable therapeutic targets and led to new effective therapies. This portion of the manuscript will also include a description of the anatomic and molecular differences between intrahepatic, hilar, and extrahepatic cholangiocarcinoma.</p><p><strong>Conclusions: </strong>Fueled by molecular discoveries, new and better diagnostic tests and therapeutic targets have improved clinical care in patients affected by liver tumors.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"e96-e102"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virtual Pathology Elective, Real Education: The PathElective.com Experience as a Model for Novel Pathology Pedagogy and a Primer for Curricular Evolution. 虚拟病理学选修课,真实教育:PathElective.com 的经验是新型病理学教学法的典范和课程改革的入门读物。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2022-0259-OA
Cullen M Lilley, Christina A Arnold, Michael A Arnold, Adam L Booth, Jerad M Gardner, Xiaoyin Sara Jiang, Sanam Loghavi, Kamran M Mirza

Context: PathElective.com was created in response to the pandemic's restrictions on interactions with trainees, and since has been incorporated into many training programs worldwide, serving as a unique means of delivering high-quality pathology and laboratory medical education at multiple levels of training.

Objective: To analyze student usage, performance, and satisfaction to provide insight into the effectiveness of virtual education to guide curricular evolution.

Design: Squarespace (Squarespace, Inc) was used for website development and to collect website analytics. Students were assessed before and after course participation using a dual-form crossover quiz design. Quiz data were anonymous and analyzed with a paired t test to account for varying student backgrounds. A novel analysis was performed aimed at examining the attrition rate of students across multiple modules.

Results: During the study period (May 1, 2020 to October 31, 2021), PathElective.com received 577 483 page views, 126 180 visits, 59 928 unique visitors, and 10 278 registered users who earned 15 305 certificates. A total of 7338 premodule and postmodule quiz pairs were analyzed. The overall average increase in score was 13.83% (P = .02). All but 5 of the 56 courses experienced a statistically significant increase in score. All courses received median scores of Very Satisfied/Satisfied in all 6 assessment domains. Aggregate attrition data revealed a unique, negative polynomial relationship (R2 = 0.656).

Conclusions: PathElective.com is a free, effective means of enhancing anatomic/clinical pathology training in medical education. These analyses offer a unique perspective on the online user experience and could guide the development of future online medical education resources.

背景:PathElective.com是为了应对大流行病对与学员互动的限制而创建的,此后被纳入全球许多培训项目,成为在多个培训级别提供高质量病理学和检验医学教育的独特手段:分析学生的使用情况、表现和满意度,以深入了解虚拟教育的有效性,从而指导课程的发展:设计:使用Squarespace(Squarespace公司)开发网站并收集网站分析数据。采用双形式交叉测验设计,在课程参与前后对学生进行评估。测验数据不记名,采用配对 t 检验进行分析,以考虑不同学生的背景。我们还进行了一项新颖的分析,旨在研究学生在多个模块中的流失率:在研究期间(2020 年 5 月 1 日至 2021 年 10 月 31 日),PathElective.com 的页面浏览量为 577 483 次,访问量为 126 180 次,独立访客为 59 928 人,注册用户为 10 278 人,获得证书 15 305 份。共分析了 7338 对模块前和模块后测验。总体平均得分提高了 13.83%(P = .02)。在 56 门课程中,除 5 门课程外,其他所有课程的得分都有显著提高。所有课程在所有 6 个评估领域的中位数分数均为 "非常满意"/"满意"。总减员数据显示了一种独特的负多项式关系(R2 = 0.656):PathElective.com是加强医学教育中解剖/临床病理学培训的一种免费、有效的手段。这些分析为在线用户体验提供了一个独特的视角,可以指导未来在线医学教育资源的开发。
{"title":"Virtual Pathology Elective, Real Education: The PathElective.com Experience as a Model for Novel Pathology Pedagogy and a Primer for Curricular Evolution.","authors":"Cullen M Lilley, Christina A Arnold, Michael A Arnold, Adam L Booth, Jerad M Gardner, Xiaoyin Sara Jiang, Sanam Loghavi, Kamran M Mirza","doi":"10.5858/arpa.2022-0259-OA","DOIUrl":"10.5858/arpa.2022-0259-OA","url":null,"abstract":"<p><strong>Context: </strong>PathElective.com was created in response to the pandemic's restrictions on interactions with trainees, and since has been incorporated into many training programs worldwide, serving as a unique means of delivering high-quality pathology and laboratory medical education at multiple levels of training.</p><p><strong>Objective: </strong>To analyze student usage, performance, and satisfaction to provide insight into the effectiveness of virtual education to guide curricular evolution.</p><p><strong>Design: </strong>Squarespace (Squarespace, Inc) was used for website development and to collect website analytics. Students were assessed before and after course participation using a dual-form crossover quiz design. Quiz data were anonymous and analyzed with a paired t test to account for varying student backgrounds. A novel analysis was performed aimed at examining the attrition rate of students across multiple modules.</p><p><strong>Results: </strong>During the study period (May 1, 2020 to October 31, 2021), PathElective.com received 577 483 page views, 126 180 visits, 59 928 unique visitors, and 10 278 registered users who earned 15 305 certificates. A total of 7338 premodule and postmodule quiz pairs were analyzed. The overall average increase in score was 13.83% (P = .02). All but 5 of the 56 courses experienced a statistically significant increase in score. All courses received median scores of Very Satisfied/Satisfied in all 6 assessment domains. Aggregate attrition data revealed a unique, negative polynomial relationship (R2 = 0.656).</p><p><strong>Conclusions: </strong>PathElective.com is a free, effective means of enhancing anatomic/clinical pathology training in medical education. These analyses offer a unique perspective on the online user experience and could guide the development of future online medical education resources.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"595-602"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10084978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Impact of the COVID-19 Pandemic on Training at the MD Anderson Cancer Center Anatomical Pathology Fellowship Program. 评估 COVID-19 大流行对 MD 安德森癌症中心解剖病理学研究员项目培训的影响。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0166-OA
Yiannis P Dimopoulos, DongHyang Kwon, Denái R Milton, Paula I Iaeger, Donna E Hansel, Victor G Prieto, Kareen E Chin, Phyu P Aung

Context: To provide high-quality, safe training during the COVID-19 pandemic, our anatomic pathology fellowship program implemented a hybrid virtual/in-person training model with supplemental digital material.

Objective: To evaluate the impact of this model.

Design: We examined Accreditation Council for Graduate Medical Education survey results and board pass rates for fellows before the pandemic (group 1); during the pandemic peak (group 2); and early and late after the pandemic peak (groups 3 and 4). Additionally, we distributed an online survey, including questions related to performance as attending physicians and fellowship experience, to recent graduates.

Results: Information loss during handover, supervision and teaching by faculty, and having at least 4 free days a month exhibited the greatest score declines between group 1 and groups 2, 3, and 4 on the Accreditation Council for Graduate Medical Education surveys. No differences were seen in board passing rates between groups. The groups did not differ in responses regarding preparation for role as attending, confidence in role as attending, or overall impression of the fellowship program. The pandemic-affected groups responded more positively on the perceived utility of supplemental digital material, impact of digital pathology on quality of education, and impact of supplemental digital material on familiarity with digital pathology. The difference was particularly large between group 1 and combined groups 3 and 4.

Conclusions: Despite the limitations noted, the hybrid training model was effective and successfully prepared fellows for their role as attending physicians. Similar studies can be informative for the implementation of similar programs or for the meaningful integration of digital pathology into training curricula.

背景:为了在COVID-19大流行期间提供高质量、安全的培训,我们的解剖病理学研究员项目实施了一种虚拟/面对面混合培训模式,并补充了数字材料:评估该模式的影响:设计:我们检查了毕业后医学教育认证委员会的调查结果以及大流行前(第 1 组)、大流行高峰期(第 2 组)、大流行高峰期后早期和晚期(第 3 组和第 4 组)研究员的考试通过率。此外,我们还向应届毕业生发放了一份在线调查问卷,其中包括与主治医师表现和研究经历相关的问题:结果:在毕业后医学教育认证委员会的调查中,第一组与第二、三、四组在交接班时的信息丢失、教师的监督和教学以及每月至少有 4 天的空闲时间等方面的得分下降幅度最大。各组之间的考试通过率没有差异。在对担任主治医师的准备情况、对担任主治医师的信心以及对研究金项目的总体印象的回答上,各组之间没有差异。受大流行病影响的组别对补充数字材料的实用性、数字病理学对教育质量的影响以及补充数字材料对熟悉数字病理学的影响的回答更为积极。第 1 组与第 3 组和第 4 组之间的差异尤其大:尽管存在一些局限性,但混合培训模式是有效的,并成功地帮助研究员为担任主治医师做好准备。类似的研究可为类似项目的实施或将数字病理学有意义地纳入培训课程提供参考。
{"title":"Assessing the Impact of the COVID-19 Pandemic on Training at the MD Anderson Cancer Center Anatomical Pathology Fellowship Program.","authors":"Yiannis P Dimopoulos, DongHyang Kwon, Denái R Milton, Paula I Iaeger, Donna E Hansel, Victor G Prieto, Kareen E Chin, Phyu P Aung","doi":"10.5858/arpa.2023-0166-OA","DOIUrl":"10.5858/arpa.2023-0166-OA","url":null,"abstract":"<p><strong>Context: </strong>To provide high-quality, safe training during the COVID-19 pandemic, our anatomic pathology fellowship program implemented a hybrid virtual/in-person training model with supplemental digital material.</p><p><strong>Objective: </strong>To evaluate the impact of this model.</p><p><strong>Design: </strong>We examined Accreditation Council for Graduate Medical Education survey results and board pass rates for fellows before the pandemic (group 1); during the pandemic peak (group 2); and early and late after the pandemic peak (groups 3 and 4). Additionally, we distributed an online survey, including questions related to performance as attending physicians and fellowship experience, to recent graduates.</p><p><strong>Results: </strong>Information loss during handover, supervision and teaching by faculty, and having at least 4 free days a month exhibited the greatest score declines between group 1 and groups 2, 3, and 4 on the Accreditation Council for Graduate Medical Education surveys. No differences were seen in board passing rates between groups. The groups did not differ in responses regarding preparation for role as attending, confidence in role as attending, or overall impression of the fellowship program. The pandemic-affected groups responded more positively on the perceived utility of supplemental digital material, impact of digital pathology on quality of education, and impact of supplemental digital material on familiarity with digital pathology. The difference was particularly large between group 1 and combined groups 3 and 4.</p><p><strong>Conclusions: </strong>Despite the limitations noted, the hybrid training model was effective and successfully prepared fellows for their role as attending physicians. Similar studies can be informative for the implementation of similar programs or for the meaningful integration of digital pathology into training curricula.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"559-565"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10466148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Debating Deposits, Redux: Substantial Interobserver Agreement Exists in Distinguishing Tumor Deposits From Nodal Metastases in Small Bowel Neuroendocrine Tumors. 沉积物之争再起波澜:在区分小肠神经内分泌肿瘤的肿瘤沉积物和结节转移方面,观察者之间的意见基本一致。
IF 3.7 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0169-OA
Raul S Gonzalez, Stefano La Rosa, Changqing Ma, Alexandros D Polydorides, Chanjuan Shi, Zhaohai Yang, Brian Cox, Dipti M Karamchandani

Context: Recent data suggest mesenteric tumor deposits (MTDs) indicate poor prognosis in small bowel well-differentiated neuroendocrine tumors (SB-NETs), including compared to positive lymph nodes, making their distinction crucial.

Objective: To study interobserver agreement in distinguishing SB-NET MTDs from positive nodes.

Design: Virtual slides from 36 locally metastatic SB-NET foci were shared among 7 gastrointestinal pathologists, who interpreted each as an MTD or a positive node. Observers ranked their 5 preferred choices among a supplied list of potentially useful histologic features, for both options. Diagnostic opinions were compared using Fleiss multirater and Cohen weighted κ analyses.

Results: Preferred criteria for MTD included irregular shape (n = 7, top choice for 5), perineural invasion/nerve entrapment (n = 7, top choice for 2), encased thick-walled vessels (n = 7), and prominent fibrosis (n = 6). Preferred criteria for positive nodes included peripheral lymphoid follicles (n = 6, top choice for 4), round shape (n = 7, top choice for 2), peripheral lymphocyte rim (n = 7, top choice for 1), subcapsular sinuses (n = 7), and a capsule (n = 6). Among 36 foci, 10 (28%) each were unanimously diagnosed as MTD or positive node. For 13 foci (36%), there was a diagnosis favored by most observers (5 or 6 of 7): positive node in 8, MTD in 5. Only 3 cases (8%) had a near-even (4:3) split. Overall agreement was substantial (κ = .64, P < .001).

Conclusions: Substantial interobserver agreement exists for distinguishing SB-NET MTDs from lymph node metastases. Favored histologic criteria in making the distinction include irregular shape and nerve/vessel entrapment for MTD, and peripheral lymphocytes/lymphoid follicles and round shape for positive nodes.

背景:最近的数据表明,肠系膜肿瘤沉积(MTDs)预示着小肠分化良好的神经内分泌肿瘤(SB-NETs)预后不良,包括与阳性淋巴结相比,因此区分它们至关重要:研究区分SB-NET MTD和阳性淋巴结的观察者间一致性:设计:来自 36 个局部转移性 SB-NET 病灶的虚拟切片由 7 位胃肠道病理学家共享,他们将每个病灶解释为 MTD 或阳性结节。在提供的潜在有用组织学特征列表中,观察者为这两个选项排列出 5 个首选项。采用弗莱斯多侧分析和科恩加权κ分析对诊断意见进行比较:MTD的首选标准包括形状不规则(7人,5人首选)、神经周围侵犯/神经卡压(7人,2人首选)、包裹的厚壁血管(7人)和突出的纤维化(6人)。阳性结节的首选标准包括外周淋巴滤泡(6 个,首选 4 个)、圆形(7 个,首选 2 个)、外周淋巴细胞边缘(7 个,首选 1 个)、囊下窦(7 个)和囊肿(6 个)。在 36 个病灶中,有 10 个病灶(28%)被一致诊断为 MTD 或阳性结节。对于 13 个病灶(36%),大多数观察者(7 人中的 5 或 6 人)倾向于一种诊断:8 个为阳性结节,5 个为 MTD。只有 3 个病例(8%)的诊断结果接近平均(4:3)。总体一致性很高(κ = .64, P < .001):结论:在区分 SB-NET MTD 和淋巴结转移方面,观察者之间存在很大的一致性。区分的首选组织学标准包括 MTD 的不规则形状和神经/血管夹层,以及阳性结节的外周淋巴细胞/淋巴滤泡和圆形。
{"title":"Debating Deposits, Redux: Substantial Interobserver Agreement Exists in Distinguishing Tumor Deposits From Nodal Metastases in Small Bowel Neuroendocrine Tumors.","authors":"Raul S Gonzalez, Stefano La Rosa, Changqing Ma, Alexandros D Polydorides, Chanjuan Shi, Zhaohai Yang, Brian Cox, Dipti M Karamchandani","doi":"10.5858/arpa.2023-0169-OA","DOIUrl":"10.5858/arpa.2023-0169-OA","url":null,"abstract":"<p><strong>Context: </strong>Recent data suggest mesenteric tumor deposits (MTDs) indicate poor prognosis in small bowel well-differentiated neuroendocrine tumors (SB-NETs), including compared to positive lymph nodes, making their distinction crucial.</p><p><strong>Objective: </strong>To study interobserver agreement in distinguishing SB-NET MTDs from positive nodes.</p><p><strong>Design: </strong>Virtual slides from 36 locally metastatic SB-NET foci were shared among 7 gastrointestinal pathologists, who interpreted each as an MTD or a positive node. Observers ranked their 5 preferred choices among a supplied list of potentially useful histologic features, for both options. Diagnostic opinions were compared using Fleiss multirater and Cohen weighted κ analyses.</p><p><strong>Results: </strong>Preferred criteria for MTD included irregular shape (n = 7, top choice for 5), perineural invasion/nerve entrapment (n = 7, top choice for 2), encased thick-walled vessels (n = 7), and prominent fibrosis (n = 6). Preferred criteria for positive nodes included peripheral lymphoid follicles (n = 6, top choice for 4), round shape (n = 7, top choice for 2), peripheral lymphocyte rim (n = 7, top choice for 1), subcapsular sinuses (n = 7), and a capsule (n = 6). Among 36 foci, 10 (28%) each were unanimously diagnosed as MTD or positive node. For 13 foci (36%), there was a diagnosis favored by most observers (5 or 6 of 7): positive node in 8, MTD in 5. Only 3 cases (8%) had a near-even (4:3) split. Overall agreement was substantial (κ = .64, P < .001).</p><p><strong>Conclusions: </strong>Substantial interobserver agreement exists for distinguishing SB-NET MTDs from lymph node metastases. Favored histologic criteria in making the distinction include irregular shape and nerve/vessel entrapment for MTD, and peripheral lymphocytes/lymphoid follicles and round shape for positive nodes.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"581-587"},"PeriodicalIF":3.7,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10483880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens. pT1 亚分类预测膀胱肿瘤标本整体切除术的无进展生存期
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-05-01 DOI: 10.5858/arpa.2023-0044-OA
Shun Sato, Takafumi Yanagisawa, Jun Miki, Yasushi Hayashida, Yohei Okada, Kosuke Iwatani, Akihiro Matsukawa, Takahiro Kimura, Shin Egawa, Masayuki Shimoda, Hiroyuki Takahashi

Context: The pathologic diagnosis of pT1 substage in conventional transurethral resection of bladder tumor specimens is inaccurate and has low interobserver reproducibility owing to fragmentation and cauterization of the specimens. En bloc resection of bladder tumor is a novel surgical procedure that improves diagnostic feasibility and accuracy in the pathologic diagnosis of bladder cancer, including depth and extent of invasion.

Objective: To examine the prognostic value of multiple pT1 subclassification methods, using only en bloc resection specimens.

Design: We examined 106 patients with T1 bladder cancer who underwent en bloc resection. The pT1 substages were assigned by 3 different subclassification methods by using the muscularis mucosae or stalk of the papillary lesion as diagnostic landmarks or millimetric depth of invasion. Intergroup differences in progression-free survival and recurrence-free survival rates were analyzed. The prognostic values of clinicopathologic factors for progression/recurrence were analyzed by using multivariate analysis.

Results: The pT1 substage was evaluable in all cases. Tumors with invasion into/beyond the muscularis mucosae and those beyond the stalk of the papillary lesion were associated with worse progression-free survival (P = .002 and P = .01, respectively). Notably, no patient with invasion confined to the stalk had disease progression during the 23-month median follow-up period. Only the pT1 subclassification method using the muscularis mucosae was an independent prognosticator of progression in multivariate analysis (P = .03).

Conclusions: Precise pathologic subclassification of invasion using en bloc resection specimens may enable accurate prognosis and assessment in patients with bladder cancer with suspicious shallow invasion.

背景:传统经尿道膀胱肿瘤切除术标本的病理诊断 pT1 亚分期不准确,而且由于标本破碎和烧灼,观察者之间的可重复性很低。膀胱肿瘤整体切除术是一种新型手术方法,可提高膀胱癌病理诊断的可行性和准确性,包括侵犯深度和范围:仅使用全切标本研究多种 pT1 亚分类方法的预后价值:我们对 106 名接受全切的 T1 膀胱癌患者进行了研究。采用3种不同的亚分类方法,以粘膜肌肉或乳头状病变的柄部作为诊断标志或以毫米为单位的浸润深度来划分pT1亚型。分析了无进展生存率和无复发生存率的组间差异。采用多变量分析法对临床病理因素对进展/复发的预后价值进行了分析:结果:所有病例的 pT1 亚分期均可评估。肿瘤侵犯粘膜肌层或超出粘膜肌层以及超出乳头状病变柄的肿瘤与较差的无进展生存期相关(分别为 P = .002 和 P = .01)。值得注意的是,在23个月的中位随访期间,没有一名侵犯范围局限于柄部的患者出现疾病进展。在多变量分析中,只有使用粘膜肌的pT1亚分类方法是疾病进展的独立预后指标(P = .03):结论:使用整体切除标本对侵犯进行精确的病理亚分类,可对可疑浅表侵犯的膀胱癌患者进行准确的预后和评估。
{"title":"pT1 Subclassification Predicts Progression-Free Survival in En Bloc Resection of Bladder Tumor Specimens.","authors":"Shun Sato, Takafumi Yanagisawa, Jun Miki, Yasushi Hayashida, Yohei Okada, Kosuke Iwatani, Akihiro Matsukawa, Takahiro Kimura, Shin Egawa, Masayuki Shimoda, Hiroyuki Takahashi","doi":"10.5858/arpa.2023-0044-OA","DOIUrl":"10.5858/arpa.2023-0044-OA","url":null,"abstract":"<p><strong>Context: </strong>The pathologic diagnosis of pT1 substage in conventional transurethral resection of bladder tumor specimens is inaccurate and has low interobserver reproducibility owing to fragmentation and cauterization of the specimens. En bloc resection of bladder tumor is a novel surgical procedure that improves diagnostic feasibility and accuracy in the pathologic diagnosis of bladder cancer, including depth and extent of invasion.</p><p><strong>Objective: </strong>To examine the prognostic value of multiple pT1 subclassification methods, using only en bloc resection specimens.</p><p><strong>Design: </strong>We examined 106 patients with T1 bladder cancer who underwent en bloc resection. The pT1 substages were assigned by 3 different subclassification methods by using the muscularis mucosae or stalk of the papillary lesion as diagnostic landmarks or millimetric depth of invasion. Intergroup differences in progression-free survival and recurrence-free survival rates were analyzed. The prognostic values of clinicopathologic factors for progression/recurrence were analyzed by using multivariate analysis.</p><p><strong>Results: </strong>The pT1 substage was evaluable in all cases. Tumors with invasion into/beyond the muscularis mucosae and those beyond the stalk of the papillary lesion were associated with worse progression-free survival (P = .002 and P = .01, respectively). Notably, no patient with invasion confined to the stalk had disease progression during the 23-month median follow-up period. Only the pT1 subclassification method using the muscularis mucosae was an independent prognosticator of progression in multivariate analysis (P = .03).</p><p><strong>Conclusions: </strong>Precise pathologic subclassification of invasion using en bloc resection specimens may enable accurate prognosis and assessment in patients with bladder cancer with suspicious shallow invasion.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"573-580"},"PeriodicalIF":4.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10218821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimation of Numbers of Testing Personnel and Test Volume in the Clinical Laboratory Improvement Amendments of 1988 Certificate of Accreditation and Certificate of Compliance Laboratories in the United States. 美国 1988 年临床实验室改进修正案》(Clinical Laboratory Improvement Amendments of 1988 Certificate of Accreditation and Certificate of Compliance Laboratories)中检测人员数量和检测量的估算。
IF 4.6 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-04-01 DOI: 10.5858/arpa.2022-0345-OA
Yang Xia, Thomas H Taylor, Jufu Chen, Jason Hsia

Context.—: Two major categories of laboratories performing nonwaived testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) are the Certificate of Accreditation (CoA) and Certificate of Compliance (CoC) laboratories. Accreditation organizations collect more detailed laboratory personnel information than the Centers for Medicare & Medicaid Services (CMS) Quality Improvement and Evaluation System (QIES).

Objective.—: To estimate total numbers of testing personnel and testing volumes in CoA and CoC laboratories, by laboratory type and state.

Design.—: We developed a statistical inference method by using the respective correlations between testing personnel counts and test volume by laboratory type.

Results.—: QIES reported 33 033 active CoA and CoC laboratories in July 2021. We estimated testing personnel to be 328 000 (95% CI, 309 000-348 000), which is supported by the count of 318 780 reported by the US Bureau of Labor Statistics. There were twice as many testing personnel in hospital laboratories as in independent laboratories (158 778 versus 74 904, P < .001). Independent laboratories had the highest test volume per person, which was twice as high as physician office laboratories (62 228 versus 30 102, P < .001). Hospital and independent laboratories comprised 34% of all CoA and CoC laboratories but performed the largest portion of testing (81%). Physician office laboratories, accounting for 44% of all CoA and CoC laboratories, performed a comparatively low proportion of total tests (9%).

Conclusions.—: Numbers of testing personnel vary considerably by laboratory type and across states. These data can provide valuable insight when assessing laboratory workforce training needs and planning for public health emergencies.

背景根据《1988 年临床实验室改进修正案》(CLIA)的规定,进行非豁免检测的实验室主要有两类,即认可证书实验室(CoA)和达标证书实验室(CoC)。与美国医疗保险与医疗补助服务中心(CMS)的质量改进与评估系统(QIES)相比,认可组织收集的实验室人员信息更为详细:按实验室类型和州估算 CoA 和 CoC 实验室的检测人员总数和检测量:我们开发了一种统计推断方法,利用各实验室类型的检测人员数量和检测量之间的相关性进行推断:2021 年 7 月,QIES 报告了 33 033 家活跃的 CoA 和 CoC 实验室。我们估计检测人员为 328 000 人(95% CI,309 000-348 000),美国劳工统计局报告的 318 780 人也支持这一估计。医院实验室的检验人员数量是独立实验室的两倍(158 778 对 74 904,P < .001)。独立实验室的人均检测量最高,是医生办公室实验室的两倍(62 228 对 30 102,P < .001)。医院和独立实验室占所有 CoA 和 CoC 实验室的 34%,但承担的检测任务最多(81%)。医生诊室实验室占所有 CoA 和 CoC 实验室的 44%,但进行的检测占总检测的比例相对较低(9%):结论:不同类型的实验室和不同州的检测人员数量差异很大。这些数据可以为评估实验室人员培训需求和规划公共卫生突发事件提供有价值的见解。
{"title":"Estimation of Numbers of Testing Personnel and Test Volume in the Clinical Laboratory Improvement Amendments of 1988 Certificate of Accreditation and Certificate of Compliance Laboratories in the United States.","authors":"Yang Xia, Thomas H Taylor, Jufu Chen, Jason Hsia","doi":"10.5858/arpa.2022-0345-OA","DOIUrl":"10.5858/arpa.2022-0345-OA","url":null,"abstract":"<p><strong>Context.—: </strong>Two major categories of laboratories performing nonwaived testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) are the Certificate of Accreditation (CoA) and Certificate of Compliance (CoC) laboratories. Accreditation organizations collect more detailed laboratory personnel information than the Centers for Medicare & Medicaid Services (CMS) Quality Improvement and Evaluation System (QIES).</p><p><strong>Objective.—: </strong>To estimate total numbers of testing personnel and testing volumes in CoA and CoC laboratories, by laboratory type and state.</p><p><strong>Design.—: </strong>We developed a statistical inference method by using the respective correlations between testing personnel counts and test volume by laboratory type.</p><p><strong>Results.—: </strong>QIES reported 33 033 active CoA and CoC laboratories in July 2021. We estimated testing personnel to be 328 000 (95% CI, 309 000-348 000), which is supported by the count of 318 780 reported by the US Bureau of Labor Statistics. There were twice as many testing personnel in hospital laboratories as in independent laboratories (158 778 versus 74 904, P < .001). Independent laboratories had the highest test volume per person, which was twice as high as physician office laboratories (62 228 versus 30 102, P < .001). Hospital and independent laboratories comprised 34% of all CoA and CoC laboratories but performed the largest portion of testing (81%). Physician office laboratories, accounting for 44% of all CoA and CoC laboratories, performed a comparatively low proportion of total tests (9%).</p><p><strong>Conclusions.—: </strong>Numbers of testing personnel vary considerably by laboratory type and across states. These data can provide valuable insight when assessing laboratory workforce training needs and planning for public health emergencies.</p>","PeriodicalId":8305,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"443-452"},"PeriodicalIF":4.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11024983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9755123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of pathology & laboratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1